In 2024, our partners enjoyed a premium opportunity to meet and network with senior decision makers from new gene therapy companies such as Sensorion, Refreshgene Therapeutics, Acousia Therapeutics, Gateway Biotechnology and Regeneron Pharmaceuticals. They demonstrated how their services are vital for companies to accelerate their gene therapy pipelines for rare genetic hearing loss.
This Niche Community of Auditory R&D Experts Seek:
Audiology & Biomarker Services
Preclinical CROs With Safety & Toxicity Services
Pathology Services
Preclinical Models For Hearing Disorders
Clinical CROs With Expertise In Inner Ear & Auditory Sciences
Why Partner In 2025?
Hear the Latest Developments in Inner Ear Drug Discovery
Discover new hearing loss therapeutics developed by industry experts, such as Refreshgene Therapeutics, Ting Therapeutics and Spiral Therapeutics, and refresh your target client list with new contacts
Establish Key Contacts with Industry Experts from Acousia Therapeutics, Sensorion, Lineage Cell Therapeutics & Regeneron
Secure precious facetime with key decision makers from the top biotech and pharma companies in the field as they require better preclinical, biomarker, pathology and clinical services to progress their drug
Generate Commercial Collaborations with New Companies Joining the Inner Ear Space
Build a wish list and have them contacted in advance to ensure that your hottest prospects are present in the room and you are all set up for success in securing top quality leads for desired commercial growth
Raise Brand Awareness within the Otolaryngology & Auditory Sciences Community
Expand your market share with key experts working on developing genetic and common hearing loss therapeutics through unique branding formats such as event branding, lead partnership options, dedicated presentations or an exhibition booth, to showcase your services in the best way possible
Audience Breakdown:
